A phase III trial of ganitumab (GAN, AMG 479) with gemcitabine (G) as first-line treatment (tx) in patients (pts) with metastatic pancreatic cancer (MPC): An analysis of safety from the GAMMA trial (GEM and AMG 479 in Metastatic Adenocarcinoma of the Pancreas).
Charles S. Fuchs
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Enzon; ImClone Systems; Infinity; Mersana; Momenta Pharm; Pfizer; Roche/Genentech; Sanofi
Masafumi Ikeda
Honoraria - Bayer Yakuhin; Dainippon Sumitomo Pharma; Novartis
Gyorgy Bodoky
No relevant relationships to disclose
Takuji Okusaka
Research Funding - Amgen
Expert Testimony - Amgen
Shinichi Ohkawa
No relevant relationships to disclose
Nobumasa Mizuno
No relevant relationships to disclose
Anna Swieboda-Sadlej
No relevant relationships to disclose
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Merck; Roche; Sanofi
Vincent Haddad
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jesse S. McGreivy
Employment or Leadership Position - Amgen
Stock Ownership - Amgen